novavax

May 6, 2021 | Maryam Shahzad

Novavax Initiates COVID-19 Vaccine Trials for Adolescents

Vaccine development company Novavax, headquartered in Gaithersburg, announced Monday that it expanded Phase 3 clinical trials for its COVID-19 vaccine candidate to include adolescents. The trials will include up to 3,000 youths ages 12-17 at up to 75 sites in the U.S., the company said in a press release. “Through the expansion of our PREVENT-19 […]

Read more

March 12, 2021 | Rachel Clair

Novavax Confirms High Vaccine Efficacy Against Original and Variant COVID-19 Strains

Novavax confirmed high levels of vaccine efficacy against both original and variant COVID-19 strains in recent United Kingdom and South Africa trials. In a press release Thursday, the Gaithersburg-based drug company said its vaccine has shown to provide 100% protection against severe disease, including hospitalizations and deaths. In a Phase 3 trial, Novavax reported a […]

Read more

February 19, 2021 | Maryam Shahzad

Altimmune Announces FDA Approval for Phase 1 COVID-19 Vaccine Clinical Trials 

Altimmune, Inc. announced Wednesday that it was approved by the FDA to begin Phase 1 clinical trials for AdCOVID, its single-dose nasal spray COVID-19 vaccine candidate. The clinical stage biopharmaceutical company, headquartered in Gaithersburg, expects to begin volunteer enrollment in the trials in the coming week, according to a statement from the company. “We believe […]

Read more

February 19, 2021 | Maryam Shahzad

Novavax to Provide 1.1 Billion COVID-19 Vaccine Doses Globally

Novavax, a vaccine development company headquartered in Gaithersburg, announced Thursday that it entered into a Memorandum of Understanding (MOU) with an international vaccine organization to provide more than 1 billion total doses of Novavax’s COVID-19 vaccine candidate, according to a statement from the company. Novavax will work with Gavi, the Vaccine Alliance to provide 1.1 […]

Read more

January 29, 2021 | Maryam Shahzad

Novavax’s Vaccine Candidate Shows Nearly 90% Efficacy in UK

Novavax, a vaccine development company headquartered in Gaithersburg, says its COVID-19 vaccine candidate showed 89.3% efficacy in UK clinical trials. The UK study enrolled more than 15,000 volunteers, according to a statement from Novavax on Thursday. More details will be released as data comes in, the company said. Phase 2b results in South Africa showed […]

Read more

January 18, 2021 | Andrea Sarralde

Novavax Busca Voluntarios para Ensayos de Vacunas COVID-19

Novavax, una empresa de desarrollo de vacunas con sede en Gaithersburg, ha iniciado la Fase 3 para su candidata a vacuna COVID-19. Es el quinto candidato en alcanzar la Fase 3 en EE. UU., después de Pfizer, Moderna, AstraZeneca y Janssen. Novavax está buscando voluntarios para participar en ensayos de vacunas, particularmente aquellos que son […]

Read more

January 15, 2021 | Maryam Shahzad

Novavax Looking for Volunteers for COVID-19 Vaccine Trials

Novavax, a vaccine development company headquartered in Gaithersburg, has initiated Phase 3 for its COVID-19 vaccine candidate.  It is the fifth candidate to reach Phase 3 in the U.S., after Pfizer, Moderna, AstraZeneca and Janssen. Novavax is looking for volunteers to participate in vaccine trials, particularly those who are part of at-risk populations like Hispanics, […]

Read more

January 4, 2021 | Andrea Sarralde

Novavax Ingresa a la Fase 3 de Pruebas para la Vacuna COVID-19

Novavax, que tiene su sede en Gaithersburg e instalaciones en Rockville, anunció que ha pasado a la Fase 3 de su ensayo de eficacia para su vacuna COVID-19. Prevent-19 está diseñado para determinar la eficacia, seguridad e inmunogenicidad de su vacuna. Se espera inscribir hasta 30.000 voluntarios en todo Estados Unidos y México, de los […]

Read more

December 31, 2020 | Suzanne Pollak

Close to ‘Finish Line,’ Novavax Enters Phase 3 Trials for COVID-19 Vaccine

Novavax, which is headquartered in Gaithersburg and has facilities in Rockville, announced it has moved into Phase 3 of its efficacy trial for its COVID-19 vaccine. Prevent-19 is designed to determine the efficacy, safety and immunogenicity of its vaccine. It expects to enroll up to 30,000 volunteers throughout the United States and Mexico, of which […]

Read more

November 16, 2020 | Maryam Shahzad

Montgomery County’s Life Sciences Industry Expanding During the Pandemic

The COVID-19 pandemic has not hurt all industries. In Montgomery County, the life sciences sector, in particular, is expanding. “The pandemic has clearly taken a huge toll on not just our economy, locally, but also as you know, nationally as well. However we still continue to see pockets of growth, especially in the life sciences,” […]

Read more

Engage us on Facebook

Follow us on Twitter